World Journal of Pharmaceutical Sciences

A new validated method for the estimation of pregabalin and etoricoxib an using high performance liquid chromatography and of its degradation

E.S.N Sumithranandan — 2022-10-01

A easy, exact, accurate, and long-lasting reverse phase RP-HPLC technique has been developed and validated for the simultaneous quantification of Pregabalin and Etorcoxib in bulk and formulation. This procedure employs a simple isocratic mobile phase of acetonitrile, a 150 x 4.6 mm, 2.7 m ascentis C18 column, with a flow rate of 0.8 ml/min of 0.01N Potassium dihydrogen phosphate (50:50). Average retention durations for pregabalin and etoricoxib were 2.313 and 2.840 minutes, respectively. Pregabalin and etoricoxib's percentage recovery were found to be 100.24% and 99.98%, respectively, showing that the approach is appropriate for routine analysis. With an R2 of 0.999 for all drugs, it was shown that Pregabalin and Etorcoxib are linear, demonstrating the approach's potential for producing results with high sensitivity. The% RSD should not exceed 2.0%, showing that the procedure is exact, according to the precision acceptance standards.

A Validated Stability Indicating RP-HPLC Method Development for Simultaneous estimation of Cabotegravir and Rilpivirine in Pharmaceutical Dosage form

Anugu Prasanna — 2022-10-01

A simple, Accurate, precise method was developed for the simultaneous estimation of the Cabotegravir and Rilpivirine in pharmaceutical dosage form. Chromatogram was run through Kromasil C18 150 x 4.6 mm, 5. Mobile phase containing Buffer 0.01N Potassium dihydrogen phosphate: Acetonitrile taken in the ratio 60:40 was pumped through column at a flow rate of 1.0 ml/min. Buffer used in this method was 0.01N Kh2PO4 buffer. Temperature was maintained at 30°C. Optimized wavelength selected was 257 nm. Retention time of Rilpivirine and Cabotegravir were found to be 2.257 min and 2.642min. %RSD of the Rilpivirine and Cabotegravir were and found to be 0.5 and 1.4 respectively. %Recovery was obtained as 100.43% and 100.13% for Rilpivirine and Cabotegravir respectively. LOD, LOQ values obtained from regression equations of Rilpivirine and Cabotegravir were 0.18, 0.54 and 0.15, 0.46 respectively. Regression equation of Cabotegravir is y = 9571.x + 4414, and y = 5378.x + 919.7 of Rilpivirine. Retention times were decreased and that run time was decreased, so the method developed was simple and economical that can be adopted in regular Quality control test in Industries.

RP-HPLC method development and validation for the simultaneous determination of elexacaftor, ivacator and tezacaftor in pharmaceutical dosage forms

Bachanaboina Shivaradha — 2022-10-01

A simple, accurate, precise method was developed for the simultaneous estimation of the Ivacaftor, Elexacaftor and Tezacaftor in bulk and tablet dosage form. Chromatogram was run through Ascentis C18 150 x 4.6 mm, 2.4m. Mobile phase containing acetonitrile & NH2PO4 in the ratio of 60:40 v/v was pumped through column at a flow rate of 1ml/min. Temperature was maintained at 30°C. Optimized wavelength for Ivacaftor, Elexacaftor and Tezacaftor was 258.0 nm. Retention time of Ivacaftor, Elexacaftor and Tezacaftor were found to be 2.798 min, 2.137 min and 3.284 min %RSD of system precision for Ivacaftor, Elexacaftor and Tezacaftor were and found to be 0.4, 0.3 and 0.5 respectively. %RSD of method precision for Ivacaftor, Elexacaftor and Tezacaftor were and found to be 0.6,0.3, and 0.5 respectively. % recovery was obtained as 99.93%, 100.07% and 100.17% for Ivacaftor, Elexacaftor and Tezacaftor respectively. LOD, LOQ values are obtained from regression equations of Ivacaftor, Elexacaftor and Tezacaftor were 0.07 ppm, 0.09 ppm, 0.02 ppm and 0.22 ppm, 0.28 ppm, 0.7 ppm respectively. Regression equation of Tezacaftor was y = 23377x + 200.3, Ivacaftor was y = 17233x + 3180 and of Elexacaftor was y = 25892x + 1146. Retention times are decreased so the method developed was simple and economical that can be adopted in regular Quality control test in Industries.

A validated stability indicating Rp-Hplc method development and validation for simultaneous estimation of serdexmethylphenidate and dexmethylphenidate in pharmaceutical dosage form

Veena Boda — 2022-10-01

A simple, Accurate, precise method was developed for the simultaneous estimation of the Serdexmethylphenidate and Dexmethylphenidate in Tablet dosage form. Chromatogram was run through Std Ascentis C18 (150 x 4.6 mm, 2.4m) Mobile phase containing Buffer 0.01N NAH2PO4: Acetonitrile taken in the ratio 60:40 was pumped through column at a flow rate of 0.9 ml/min. Buffer used in this method was 0.01N NAH2PO4 buffer. Temperature was maintained at 30°C. Optimized wavelength selected was 228 nm. Retention time of Serdexmethylphenidate and Dexmethylphenidate were found to be 2.133 min and 2.925 min. %RSD of the Serdexmethylphenidate and Dexmethylphenidate were and found to be 0.6 and 0.4 respectively. %Recovery was obtained as 99.98% and 100.50% for Serdexmethylphenidate and Dexmethylphenidate respectively. LOD, LOQ values obtained from regression equations of Serdexmethylphenidate and Dexmethylphenidate were 0.24, 0.73 µg/ml and 0.04, 0.12µg/ml respectively. Regression equation of Serdexmethylphenidate is y = 71326x + 10084, and y = 85514x + 10852.of Dexmethylphenidate. Retention times were decreased and that run time was decreased, so the method developed was simple and economical that can be adopted in regular Quality control test in Industries.